Coherus Oncology (CHRS) vs Precision BioSciences (DTIL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Precision BioSciences (DTIL) has outperformed Coherus Oncology (CHRS) over the past year, gaining 12.8% versus a loss of 39.2%. Over five years, CHRS leads with a -93.7% price change compared with -97.8% for DTIL. Precision BioSciences is the larger company by market cap ($177.5 million vs $165.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CHRS | DTIL |
|---|---|---|
| Share price | $1.07 | $6.43 |
| Market cap | $165.32M | $177.48M |
| 1-day change | +5.94% | +2.88% |
| YTD return | -24.65% | +54.57% |
| 1-year return | -39.20% | +12.81% |
| 5-year return | -93.71% | -97.81% |
| EPS (TTM) | $-1.25 | $-1.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.62 | $9.62 |
| 52-week low | $0.974 | $3.53 |
| Distance from 52-week high | -59.10% | -33.16% |
| Analyst consensus | none | none |
| Avg. price target upside | +624.30% | +357.23% |
| Average volume | 1.16M | 287.13K |
| Shares outstanding | 154.50M | 27.60M |
| Employees | 144 | 67 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DTIL has outperformed CHRS by 52.0 percentage points over the past year.
About Coherus Oncology
CHRS stock →Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees
About Precision BioSciences
DTIL stock →Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 67 employees
CHRS vs DTIL FAQ
Which is bigger, Coherus Oncology or Precision BioSciences?
Precision BioSciences (DTIL) is larger, with a market capitalization of $177.48M compared with $165.32M for Coherus Oncology (CHRS).
Which stock has performed better over the past year, CHRS or DTIL?
DTIL returned +12.81% over the past 12 months, compared with -39.20% for CHRS (price return, excluding dividends). Past performance does not predict future results.
Are Coherus Oncology and Precision BioSciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.